11th Edition of Clinical Trials on Alzheimer Disease

P143 - Baseline characterization of the European prevention of Alzheimer’s dementia (EPAD) longitudinal cohort
study (LCS)
Michael T. Ropacki, PhD , John Harrison, PhD, Joel Kramer, PsyD
, Christopher Randolph, PhD, Jeffrey Kaye, MD, Bruce Albala, PhD, Karen
Ritchie, PhD

OC37 - Pros and cons of AD composite endpoints considering recently revised regulatory
guidance and 2018 NIA-AA research framework
Michael T. Ropacki, PhD , Suzanne Hendrix, PhD

http://www.ctad-alzheimer.com/files/files/CTA...t%20BD.pdf

In case you forgot who Dr. Ropacki, PhD is:

Amarantus Appoints Michael T. Ropacki, PhD as Chief Medical Advisor for Alzheimer's Blood Diagnostic LymPro Test Program - APRIL 16, 2018

https://www.amarantus.com/news/press-releases...ef-medical